Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of California, San Francisco
Gilead Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Washington
Astellas Pharma Inc
Hoffmann-La Roche
University of Florida
Nanjing Leads Biolabs Co.,Ltd
Merck Sharp & Dohme LLC
Stichting Hemato-Oncologie voor Volwassenen Nederland
Medical College of Wisconsin
Hospital Universitario Dr. Jose E. Gonzalez
Alliance for Clinical Trials in Oncology
University of California, San Francisco
Eastern Cooperative Oncology Group
Hoffmann-La Roche
University of Arizona
BioNTech SE
Janssen Research & Development, LLC
Thomas Jefferson University
Corcept Therapeutics
M.D. Anderson Cancer Center
Intergroupe Francophone de Cancerologie Thoracique
AstraZeneca
Gruppo Oncologico Italiano di Ricerca Clinica